Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.
Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.
The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.
Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.
One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.
With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.
Bio-Rad Laboratories reported Q3 2022 net sales of $680.8 million, down 8.9% from Q3 2021. COVID-related revenue declined to $17 million from $57 million in the previous year. The Life Science segment saw a 14.9% decrease in net sales, while Clinical Diagnostics dipped 2.8%. The company posted a net loss of $164.2 million, or $5.52 per share, compared to net income of $3.9 billion or $129.96 per share in Q3 2021. The non-GAAP outlook for 2022 anticipates currency-neutral revenue growth at the high end of 1-2% guidance.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its third-quarter 2022 financial results on October 27, 2022, after market close. A conference call discussing these results is scheduled for 2 PM Pacific Time the same day. Bio-Rad, a leader in life science research and clinical diagnostics, generated $2.9 billion in revenues for 2021 and employs approximately 7,900 individuals worldwide. Investors can access a live webcast via the 'Investor Relations' section of the company's website.
Bio-Rad Laboratories (NYSE: BIO) has announced the acquisition of Curiosity Diagnostics for up to $170 million, comprising $100 million in cash and $70 million in future milestones. Curiosity, based in Poland, is developing a rapid diagnostics PCR system for the molecular diagnostics market. This acquisition aims to enhance Bio-Rad's Clinical Diagnostics Group, expanding into near-patient molecular diagnostics. With Bio-Rad's extensive market presence and Curiosity's innovative technology, the deal is anticipated to improve product offerings and market reach.
Bio-Rad Laboratories (NYSE: BIO, BIO.B) reported Q2 2022 net sales of $691.1 million, down 3.5% year-over-year, with COVID-related revenue falling to approximately $33 million. Currency-neutral sales recorded a 0.5% increase. Life Science segment sales decreased by 3.5% to $322.4 million, while Clinical Diagnostics fell 3.3% to $367.8 million. A significant net loss of $927.2 million was reported versus a net income of $914.1 million in Q2 2021, largely due to equity securities valuation changes. The full-year outlook remains positive with expected revenue growth and an increased share repurchase program of $200 million.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q2 2022 on July 28, 2022, after market close. A conference call is scheduled for 3 PM Pacific Time (6 PM Eastern Time) to discuss these results. Investors can participate by calling 844-200-6205 within the U.S. or +1 929-526-1599 internationally, access code: 715914. A live webcast will also be available.
Bio-Rad Laboratories, Inc. reported Q1 2022 net sales of $700.1 million, down 3.7% from Q1 2021. Excluding COVID-related sales, revenue increased 6.5% on a currency-neutral basis, driven by strong growth in Process Media and Droplet Digital PCR products. The net loss for the quarter was $3.37 billion or $112.57 per share, significantly impacted by changes in the fair market value of equity securities. Non-GAAP net income was $149.1 million, or $4.94 per diluted share. The company anticipates 1.0% to 2.0% revenue growth for FY 2022.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q1 2022 on April 28, 2022, after the market closes. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). The company, a leader in life science research and clinical diagnostics, had revenues of $2.9 billion in 2021 and has been operational since 1952, serving a global customer base focused on advancing healthcare.
Bio-Rad Laboratories, Inc. (NYSE: BIO) has successfully closed an underwritten public offering of $1.2 billion in aggregate principal amount of notes. The offering consists of $400 million due in 2027 and $800 million due in 2032, with interest rates of 3.300% and 3.700%, respectively. The proceeds will be used for general corporate purposes, including working capital and potential acquisitions. Major banks such as Citigroup, Goldman Sachs, and J.P. Morgan managed the offering. Bio-Rad reported revenues of $2.9 billion in 2021.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is hosting an investor day in New York City, highlighting its growth strategy and financial targets. The company aims for a 9% core revenue CAGR from 2021 to 2025 and a 28% adjusted EBITDA margin by 2025. Bio-Rad emphasizes portfolio transformation and expansion in the biopharma sector. The Life Science Research and Clinical Diagnostics segments are expected to drive growth through advanced products and solutions. Bio-Rad has consistently exceeded its previous financial targets, setting a positive outlook for future performance.
FAQ
What is the current stock price of Bio-Rad Laboratories (BIO)?
What is the market cap of Bio-Rad Laboratories (BIO)?
What does Bio-Rad Laboratories, Inc. specialize in?
When was Bio-Rad Laboratories founded?
Where is Bio-Rad Laboratories headquartered?
What are the core business segments of Bio-Rad?
What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?
How many employees does Bio-Rad have?
What is Bio-Rad's involvement in the biopharmaceutical industry?
What is Bio-Rad's market reach?
What is the significance of Bio-Rad's ownership in Sartorius?
How does Bio-Rad contribute to scientific research and development?
